Zurich, SWITZERLAND – 16 April 2015. Sequana Medical, a Swiss-based medical device company, announced today that it has entered into an agreement with Fresenius Medical Care to commercialize its innovative alfapump system.
The alfapump system is an automated, fully implantable pump system for the management of ascites. Ascites is a frequent complication of late-stage liver disease and certain cancers, and affects hundreds of thousands of patients across the world.
Under the terms of the agreement, Fresenius Medical Care has the rights to distribute the alfapump system across Europe, Middle East and Africa markets not currently serviced by Sequana Medical’s own distribution channels. The first countries to go live are Austria, Belgium, the Netherlands and Poland. Fresenius Medical Care will also engage in collaborative market development and reimbursement programs in these markets.
The alfapump system is the first real alternative to large-volume paracentesis, a lengthy, invasive and painful procedure which can require weekly hospital visits for drainage of excess fluid. By moving ascites to the bladder as it forms, the alfapump system prevents the build-up of fluid and its complications, improving patient quality of life and reducing hospital visits.
Sequana Medical has recently launched its next generation product, alfapump with DirectLink Technology, which allows clinicians to monitor the alfapump remotely. The Company also began an FDA trial of the alfapump system earlier this month.
Gunther Klotz, Executive Vice President Central Europe & Northern Europe, Fresenius Medical Care commented: "The alfapump is a unique innovation that both improves the quality of healthcare and reduces the cost and burden of managing refractory ascites. Together with our Prometheus System, the alfapump therapy will strengthen our portfolio in the management of liver disease. We are delighted to be working with Sequana Medical to bring this therapy to a greater audience.”
Dr. Noel L. Johnson, CEO, Sequana Medical added: "We are very excited about this agreement with Fresenius Medical Care, proven market leader and visionary in fluid management. Fresenius Medical has made a commitment to the alfapump therapy and will now leverage their distribution and marketing capabilities to accelerate its adoption and usage throughout the targeted markets. This is the first of several strategic initiatives we are working on to partner with world-class medical device companies to apply our technology to improve the management of patients suffering from fluid
overload. Ascites management is an area of significant unmet clinical need and represents more than a €1 billion market opportunity within the EMEA markets.”